Theratechnologies Inc (TSE:TH) had its target price lifted by National Bank Financial from C$9.25 to C$9.75 in a research note issued to investors on Thursday. The firm currently has an outperform rating on the stock. National Bank Financial also issued estimates for Theratechnologies’ Q3 2017 earnings at ($0.02) EPS and FY2017 earnings at ($0.16) EPS.
Separately, Scotiabank reiterated an outperform rating and issued a C$9.50 target price on shares of Theratechnologies in a research note on Wednesday, June 21st.
Shares of Theratechnologies (TSE:TH) opened at 7.86 on Thursday. The firm has a 50-day moving average price of $7.55 and a 200 day moving average price of $7.18. Theratechnologies has a 52-week low of $2.61 and a 52-week high of $8.72. The stock’s market cap is $584.90 million.
ILLEGAL ACTIVITY NOTICE: “Theratechnologies Inc (TH) Given New C$9.75 Price Target at National Bank Financial” was first reported by Transcript Daily and is the property of of Transcript Daily. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of United States and international copyright and trademark legislation. The correct version of this piece of content can be accessed at https://transcriptdaily.com/2017/10/09/theratechnologies-inc-th-given-new-c9-75-price-target-at-national-bank-financial.html.
Theratechnologies Company Profile
Theratechnologies Inc is a specialty pharmaceutical company. The Company addresses medical needs to promote healthy living among human immunodeficiency virus (HIV) patients. Its products include EGRIFTA and Ibalizumab. EGRIFTA (tesamorelin for injection) refers to tesamorelin and it is indicated for the reduction of excess abdominal fat in HIV infected patients with lipodystrophy.
Receive News & Ratings for Theratechnologies Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theratechnologies Inc and related companies with MarketBeat.com's FREE daily email newsletter.